Anaptysbio (ANAB) closed at $46.25 on November 13, 2026, down 3.2% from the previous close, on volume of 464,016 shares (30-day average 424,132).
Data as of November 13, 2026.
Leerink Partners Remains a Buy on AnaptysBio (ANAB)
TipRanks (Mon, 16-Nov 8:45 AM ET)
TipRanks (Fri, 13-Nov 12:40 PM ET)
Piper Sandler Keeps Their Buy Rating on AnaptysBio (ANAB)
TipRanks (Fri, 13-Nov 9:08 AM ET)
TipRanks (Fri, 13-Nov 8:50 AM ET)
AnaptysBio GAAP EPS of $0.11 misses by $0.28, revenue of $30.27M misses by $3.19M
Seeking Alpha News (Thu, 12-Nov 4:42 PM ET)
Anaptys Reports Fiscal First Quarter 2027 Financial Results and Provides Business Update
Globe Newswire (Thu, 12-Nov 4:15 PM ET)
Anaptys Announces Participation in Upcoming Investor Conferences
Globe Newswire (Tue, 10-Nov 4:20 PM ET)
Globe Newswire (Mon, 19-Oct 2:18 PM ET)
Globe Newswire (Mon, 21-Sep 4:15 PM ET)
Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
Globe Newswire (Tue, 1-Sep 4:15 PM ET)
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Anaptysbio trades on the NASDAQ stock market under the symbol ANAB.
As of November 16, 2026, ANAB stock price declined to $45.39 with 171,756 million shares trading.
ANAB has a beta of 0.81, meaning it tends to be less sensitive to market movements. ANAB has a correlation of 0.02 to the broad based SPY ETF.
ANAB has a market cap of $1.35 billion. This is considered a Small Cap stock.
Last quarter Anaptysbio reported $30 million in Revenue and $.11 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.40.
In the last 3 years, ANAB traded as high as $72.36 and as low as $6.11.
The top ETF exchange traded funds that ANAB belongs to (by Net Assets): VTI, XBI, IWM, VXF, IBB.
ANAB has outperformed the market in the last year with a return of +172.9%, while the SPY ETF gained +11.8%. However, in the most recent history, ANAB shares have underperformed the stock market with its stock returning -19.0% in the last 3 month period and -6.0% for the last 2 week period, while SPY has returned -4.2% and -1.6%, respectively.
ANAB support price is $44.59 and resistance is $47.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANAB shares will trade within this expected range on the day.